Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 16/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 16/20 | 1.00 |
| ▸ | GABRP | O00591 | 6/20 | 1.00 |
| ▸ | GABRD | O14764 | 6/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 6/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 6/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 6/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 6/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 6/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 6/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 6/20 | 1.00 |
| ▸ | GABRE | P78334 | 6/20 | 1.00 |
| ▸ | GABRA6 | Q16445 | 6/20 | 1.00 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 1.00 |
| ▸ | GABRG3 | Q99928 | 6/20 | 1.00 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gabazine SCHEMBL5473649 | 0.99 | GABRA1 (0.98) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| Gabazine SCHEMBL16320027 | 0.98 | GABRA1 (0.95) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| SCHEMBL28620347 | 0.93 | GABRA1 (0.86) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| SCHEMBL26665197 | 0.85 | GABRA1 (1.00) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| SCHEMBL28635070 | 0.83 | GABRA1 (0.71) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| Bromide SCHEMBL17927694 | 0.82 | GABRA1 (1.00) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| Hydrochloric Acid SCHEMBL16320560 | 0.81 | GABRA1 (0.95) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| SCHEMBL28635088 | 0.81 | GABRA1 (0.67) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| SCHEMBL2739432 | 0.80 | GABRA1 (0.90) | GABRA1GABRB2GABRPGABRDGABRB1 | |
| SCHEMBL415236 | 0.79 | GABRA1 (0.65) | GABRA1GABRB2GABRPGABRDGABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116913-A1 | NEUROSTEROID COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USE IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TEXAS A & M UNIV SYS (US) | 2026-04-30 | — | — | US | disclosed |
| US-12509487-B2 | Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2025-12-30 | — | — | US | disclosed |
| WO-2025262072-A2 | NEURONAL DRUG SCREENING METHOD AND NEW APPLICATIONS FOR DILAZEP AND PENBUTOLOL | MIĘDZYNARODOWY INSTYTUT BIOLOGII MOLEKULARNEJ I KOMÓRKOWEJ (PL) | 2025-12-26 | — | — | WO | disclosed |
| EP-4528274-A2 | BIOMARKERS FOR NEUROPATHOLOGICAL CONDITIONS AND METHODS FOR DIAGNOSIS AND MONITORING THE EFFICACY OF TREATMENT | Instituto de Medicina Molecular João Lobo Antunes (PT) | 2025-03-26 | — | — | EP | disclosed |
| US-12173313-B2 | Assembly of functionally integrated human forebrain spheroids and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-12-24 | — | — | US | disclosed |
| EP-4125999-B1 | TRKB-FL BASED POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | INST DE MEDICINA MOLECULAR JOAO LOBO ANTUNES (PT) | 2024-11-06 | — | — | EP | disclosed |
| US-20240325760-A1 | METHODS FOR DETECTING AND PREVENTING ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-10-03 | — | — | US | disclosed |
| EP-4433468-A1 | COMPOSITIONS AND METHODS FOR PRESERVING AND/OR RESTORING NEURAL FUNCTION | The Regents of the University of California (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20240034765-A1 | SCG2 NEUROPEPTIDES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-02-01 | — | — | US | disclosed |
| EP-3600362-B1 | ASSEMBLY OF FUNCTIONALLY INTEGRATED HUMAN FOREBRAIN SPHEROIDS AND METHODS OF USE THEREOF | UNIV LELAND STANFORD JUNIOR (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | Sunovion Inc. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | Sunovion Inc. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8097625-B2 | Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression | SUNOVION PHARMACEUTICALS INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097625-B2 | Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression | SUNOVION PHARMACEUTICALS INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2343073-A2 | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression | Sepracor Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20070299055-A1 | COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299055-A1 | COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2005063297-A2 | MELATONIN COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | SEPRACOR INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005063248-A1 | MODAFINIL COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | SEPRACOR INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005060968-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299055-A1 | COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | HTR2A, HTR5A, HTR2C | GABRA1 54/4885GABRB2 61/4885GABRP 72/4885 |
| US-12509487-B2 | Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders | SLC6A11, GABRE, SLC6A13 | GABRA1 29/4885GABRB2 33/4885GABRP 27/4885 |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | HTR2A, HTR5A, HTR2C | GABRA1 46/4885GABRB2 58/4885GABRP 74/4885 |
| US-20260116913-A1 | NEUROSTEROID COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USE IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | CHRNA9, HSD3B2, HSD3B1 | GABRA1 279/4885GABRB2 241/4885GABRP 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.